Overview

Transgender Estradiol Affirming Therapy

Status:
Recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this open label, pilot, randomized clinical trial is to evaluate the effectiveness, safety and tolerability of estrogen use in transgender female and the degree of testosterone suppression achieved in this population when placed on gender affirming pharmacological therapy.
Phase:
Phase 3
Details
Lead Sponsor:
Washington University School of Medicine
Treatments:
Hormones
Spironolactone